Entrovas Tablet 49 mg+51 mg contains a combination of Sacubitril and Valsartan, which is used in the treatment of chronic heart failure with reduced ejection fraction (HFrEF). This combination medicine belongs to a class known as angiotensin receptor neprilysin inhibitors (ARNIs) and is designed to improve heart function, reduce symptoms, and lower the risk of hospitalization and cardiovascular death in patients with heart failure.

Heart failure occurs when the heart is unable to pump blood effectively, leading to symptoms such as shortness of breath, fatigue, swelling in the legs, and reduced exercise tolerance. Entrovas Tablet helps the heart work more efficiently by relaxing blood vessels, reducing fluid buildup, and improving blood flow throughout the body.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each tablet contains:

• Sacubitril 49 mg

• Valsartan 51 mg

Mechanism of Action

Entrovas Tablet works through the combined action of its two active ingredients:

Sacubitril
Sacubitril is a neprilysin inhibitor. It blocks the enzyme neprilysin, which normally breaks down beneficial peptides in the body. By inhibiting neprilysin, Sacubitril increases the levels of natriuretic peptides, which help:

• Relax blood vessels

• Reduce blood pressure

• Promote sodium and water excretion

• Decrease strain on the heart

Valsartan
Valsartan is an angiotensin II receptor blocker (ARB). It works by blocking the effects of angiotensin II, a substance that causes blood vessels to narrow. This helps:

• Dilate blood vessels

• Lower blood pressure

• Reduce workload on the heart

Together, these two medicines help improve heart function and reduce the progression of heart failure.

Indications

Entrovas Tablet 49 mg+51 mg is indicated for:

• Chronic heart failure with reduced ejection fraction (HFrEF)

• Reducing the risk of cardiovascular death and hospitalization due to heart failure

• Improving symptoms such as breathlessness, fatigue, and swelling

It is often used as a replacement for ACE inhibitors or ARBs in patients with heart failure who require improved outcomes.

Dosage and Administration

The dosage should always be determined by a physician based on the patient’s condition.

General guidelines include:

• Usually one tablet twice daily

• Can be taken with or without food

• Swallow the tablet whole with a glass of water

• Patients previously taking an ACE inhibitor should stop it at least 36 hours before starting this medication

Regular monitoring of blood pressure, kidney function, and potassium levels is recommended during treatment.

Precautions

Before taking Entrovas Tablet, inform your doctor if you:

• Have kidney disease or liver impairment

• Have a history of angioedema

• Have low blood pressure

• Are pregnant or planning pregnancy

• Are taking ACE inhibitors, ARBs, or potassium supplements

This medication is not recommended during pregnancy due to potential risk to the fetus.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Some patients may experience side effects, including:

Common side effects:

• Low blood pressure (hypotension)

• Dizziness or lightheadedness

• Increased potassium levels

• Reduced kidney function

Less common but serious side effects:

• Angioedema (swelling of face, lips, or throat)

• Severe hypotension

• Kidney impairment

If severe symptoms occur, immediate medical attention should be sought.

Storage

• Store below 25°C in a cool and dry place

• Protect from moisture and direct sunlight

• Keep out of reach of children

Entrovas Tablet 49 mg+51 mg is an advanced therapy for heart failure management, helping improve heart function, reduce symptoms, and lower the risk of serious cardiovascular complications.